Merck & Co., Inc. (ETR:6MK)
75.00
-0.50 (-0.66%)
Oct 10, 2025, 5:35 PM CET
Merck & Co. Revenue
Merck & Co. had revenue of $15.81B USD in the quarter ending June 30, 2025, a decrease of -1.90%. This brings the company's revenue in the last twelve months to $63.62B, up 1.82% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$63.62B
Revenue Growth
+1.82%
P/S Ratio
3.41
Revenue / Employee
$848.21K
Employees
75,000
Market Cap
184.78B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
Dec 31, 2019 | 39.12B | -3.17B | -7.50% |
Dec 31, 2018 | 42.29B | 2.17B | 5.41% |
Dec 31, 2017 | 40.12B | 315.00M | 0.79% |
Dec 31, 2016 | 39.81B | 309.00M | 0.78% |
Dec 31, 2015 | 39.50B | -2.74B | -6.48% |
Dec 31, 2014 | 42.24B | -1.80B | -4.08% |
Dec 31, 2013 | 44.03B | -3.23B | -6.84% |
Dec 31, 2012 | 47.27B | -780.00M | -1.62% |
Dec 31, 2011 | 48.05B | 2.06B | 4.48% |
Dec 31, 2010 | 45.99B | 18.56B | 67.66% |
Dec 31, 2009 | 27.43B | 3.58B | 15.00% |
Dec 31, 2008 | 23.85B | -347.70M | -1.44% |
Dec 31, 2007 | 24.20B | 13.60B | 128.41% |
Dec 31, 2006 | 10.59B | 1.09B | 11.42% |
Dec 31, 2005 | 9.51B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Sartorius Aktiengesellschaft | 3.47B |
Fresenius Medical Care AG | 19.52B |
Fielmann Group AG | 2.40B |
Carl Zeiss Meditec AG | 2.18B |
Merck & Co. News
- 1 day ago - High Margins, Lower Price: Is This Merck Stock's Buying Window? - Forbes
- 2 days ago - Behind the Scenes of Merck & Co's Latest Options Trends - Benzinga
- 2 days ago - Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025 - Wallstreet:Online
- 2 days ago - Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025 - Business Wire
- 2 days ago - Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025 - Business Wire
- 3 days ago - MERCK INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewsWire
- 3 days ago - Vaccine debate heats up as officials weigh splitting combined MMR into single doses - Fox News
- 4 days ago - Merck (MRK) Declines More Than Market: Some Information for Investors - Nasdaq